Data gathered: May 31
Alternative Data for Inhibikase Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,919 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
| Price | $2.01 |
| Target Price | Sign up |
| Volume | 67,720 |
| Market Cap | $155M |
| Year Range | $1.13 - $3.97 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Stifel Financial Corp Invests $43,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 17 - ETF Daily News |
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14 - Finnhub |
|
|
Barclays PLC Buys New Stake in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 12 - ETF Daily News |
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)May 4 - Finnhub |
|
 |
Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAHMay 1 - SeekingAlpha |
 |
Inhibikase Therapeutics announces appointment of McIntyre as CFOApril 14 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -14M | -16M | |
| Q4 '24 | 26,000 | 13,000 | 13,000 | -12M | -13M | -0.175 |
| Q3 '24 | 0 | 0 | 0 | -5.8M | -5.8M | -0.650 |
| Q2 '24 | 0 | 6,600 | -6,600 | -5M | -5M | -0.660 |
| Q1 '24 | 0 | 6,600 | -6,600 | -4.6M | -4.8M | -0.730 |
Insider Transactions View All
| Munshi Amit filed to buy 365,000 shares at $1.4. October 23 '24 |
| Kush Arvind filed to buy 145,000 shares at $1.4. October 23 '24 |
| Bellini Roberto filed to buy 1,460,000 shares at $1.4. October 23 '24 |
| Werner Milton H. filed to buy 5,335,433 shares at $0.8. August 16 '22 |
Similar companies
Read more about Inhibikase Therapeutics (IKT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Inhibikase Therapeutics?
The Market Cap of Inhibikase Therapeutics is $155M.
What is the current stock price of Inhibikase Therapeutics?
Currently, the price of one share of Inhibikase Therapeutics stock is $2.01.
How can I analyze the IKT stock price chart for investment decisions?
The IKT stock price chart above provides a comprehensive visual representation of Inhibikase Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Inhibikase Therapeutics shares. Our platform offers an up-to-date IKT stock price chart, along with technical data analysis and alternative data insights.
Does IKT offer dividends to its shareholders?
As of our latest update, Inhibikase Therapeutics (IKT) does not offer dividends to its shareholders. Investors interested in Inhibikase Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Inhibikase Therapeutics?
Some of the similar stocks of Inhibikase Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.